Axitinib

Category: Cancer



Axitinib Overview

Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[2] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[3] and several other tumour types.[4] It was approved for RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free surviv...

Read more Axitinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Axitinib

Recent Axitinib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Axitinib
  • Tablet: 1mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Axitinib or a similar ingredient: (1 result)

Related Axitinib Topics:

axitinib
angiogenesis inhibitor...




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA